At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02652 CF PHARMTECH
Trading 01-14 15:06:26
31.760
+0.040
+0.13%
High32.120
Low31.700
Vol45.50K
Open31.740
D1 Closing31.720
Amplitude1.32%
Mkt Cap13.09B
Tradable Cap9.60B
Total Shares412.00M
T/O1.45M
T/O Rate0.02%
Tradable Shares302.22M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation
CF PHARMTECH (02652): Company's Leading Inhaled Nucleic Acid Drug Development Project Selected for Jiangsu Province's 2025 Major Sci-Tech Program "Innovative Biopharmaceuticals"
CF PharmTech Inc is a China-based company primarily focused on the research & development, manufacturing and commercialization of inhalation technologies and inhalation drugs. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Company's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The Company mainly conducts its business in the domestic market.